The scientist’s investigation covers issues in Breast cancer, Internal medicine, Endocrinology, Cancer research and Cancer. His Breast cancer course of study focuses on Bioinformatics and Drug resistance, Gene expression profiling and Comparative genomic hybridization. Per Eystein Lønning has researched Gene expression profiling in several fields, including DNA microarray, Breast cancer classification and Triple-Negative Breast Carcinoma.
His research on Internal medicine often connects related areas such as Oncology. His Endocrinology research incorporates themes from In vivo and Aminoglutethimide. His Cancer research research integrates issues from CHEK2, Carcinogenesis, Gene, Genotype and Metastasis.
Per Eystein Lønning mainly focuses on Internal medicine, Breast cancer, Oncology, Endocrinology and Aromatase. The various areas that he examines in his Breast cancer study include Cancer research, Chemotherapy and Bioinformatics. His Cancer research study also includes
His studies in Oncology integrate themes in fields like Colorectal cancer, Gynecology, Adjuvant therapy and Pathology. He interconnects In vivo and Aminoglutethimide in the investigation of issues within Endocrinology. His Aromatase research incorporates elements of Megestrol acetate, Adjuvant and Pharmacology.
Per Eystein Lønning mostly deals with Internal medicine, Breast cancer, Oncology, Cancer research and Cancer. His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Mdm2. His Breast cancer research incorporates elements of Germline mutation, Estrogen and PTEN.
His Oncology research is multidisciplinary, incorporating elements of Chemotherapy, Case-control study, Tamoxifen, Ovarian cancer and Genotype. His research integrates issues of DNA methylation, Apoptosis and Downregulation and upregulation, Gene, microRNA in his study of Cancer research. His biological study spans a wide range of topics, including DNA microarray and Gene expression profiling.
Per Eystein Lønning mainly investigates Internal medicine, Oncology, Cancer research, Cancer and Breast cancer. He has researched Oncology in several fields, including Quiescent state, Case-control study, Genotype, Hepatectomy and Colorectal cancer. His work carried out in the field of Cancer research brings together such families of science as Mutation, Primary tumor, Carcinogenesis and Transcription factor.
His Cancer research is multidisciplinary, relying on both Angiogenesis and Mitochondrion. The Breast cancer study which covers Germline mutation that intersects with CA15-3. His Aromatase inhibitor study combines topics from a wide range of disciplines, such as Antiestrogen, Estrogen and Combination therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Molecular portraits of human breast tumours
Charles M. Perou;Therese Sørlie;Michael B. Eisen;Matt van de Rijn.
Nature (2000)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Therese Sørlie;Charles M. Perou;Robert Tibshirani;Turid Aas.
Proceedings of the National Academy of Sciences of the United States of America (2001)
Repeated observation of breast tumor subtypes in independent gene expression data sets
Therese Sørlie;Robert Tibshirani;Joel Parker;Trevor Hastie.
Proceedings of the National Academy of Sciences of the United States of America (2003)
A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.
R. C Coombes;E. Hall;L. J. Gibson;R. Paridaens.
The New England Journal of Medicine (2004)
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors
Jonathan R. Pollack;Therese Sørlie;Charles M. Perou;Christian A. Rees.
Proceedings of the National Academy of Sciences of the United States of America (2002)
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
RC Coombes;LS Kilburn;CF Snowdon;R Paridaens.
The Lancet (2007)
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
Turid Aas;Anne Lise Børresen;Stephanie Geisler;Birgitte Smith-Sørensen.
Nature Medicine (1996)
Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays
Jonathan R. Pollack;Charles M. Perou;Therese Sorlie;Ash A. Alizadeh.
Nature Genetics (1999)
Long-term Cultures of Bone Marrow–Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation
Gro Vatne Røsland;Agnete Svendsen;Anja Torsvik;Ewa Sobala.
Cancer Research (2009)
Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study
Jürgen Geisler;Ben Haynes;Gun Anker;Mitch Dowsett.
Journal of Clinical Oncology (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Oslo University Hospital
Breast Cancer Research Foundation
Oslo University Hospital
University of Bergen
University of Bergen
Norwegian University of Science and Technology
Norwegian University of Science and Technology
Norwegian University of Science and Technology
University of Bristol
Haukeland University Hospital
Johns Hopkins University
University of Strasbourg
Soochow University
Peking University
University of California, Davis
University of Massachusetts Lowell
University of Southampton
World Health Organization
University of Zurich
University of Turku
The University of Texas Health Science Center at Houston
Yale University
Tulane University
Monash University
Leuphana University of Lüneburg
National Bureau of Economic Research